INOTIV INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
INOTIV INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
PR Newswire
NEW ORLEANS, La., April 19, 2024
NEW ORLEANS, La., April 19, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inotiv, Inc. (NasdaqCM: NOTV).
On November 5, 2021, the Company completed its purchase of Envigo RMS, LLC ("Envigo") after several months of discussion and due diligence reviews. However, from July 2021 onward, Envigo's Cumberland Facility had been charged with numerous serious violations, many repeated, of the Animal Welfare Act ("AWA") for cruel and inhumane treatment of dogs intended for scientific research use. The violations culminated with the execution of a federal search warrant at the facility on May 18, 2022 and a lawsuit filed on May 19, 2022 by the U.S. Attorney General against Envigo for violations of the AWA. Notably, the Company failed to detect and/or otherwise remedy the serial violations by Envigo during its supposed due diligence reviews and multiple inspections during the acquisition process of Envigo, or to disclose the violations to shareholders.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, which remains ongoing. Recently, the court presiding over that case denied the Company's motion to dismiss, allowing the case to move forward.
KSF's investigation is focusing on whether Inotiv's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Inotiv shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-notv/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163
View original content to download multimedia:https://www.prnewswire.com/news-releases/inotiv-investigation-continued-by-former-louisiana-attorney-general-kahn-swick--foti-llc-continues-to-investigate-the-officers-and-directors-of-inotiv-inc---notv-302122469.html
SOURCE Kahn Swick & Foti, LLC
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom